Press Releases

WATERTOWN, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker , Chief Executive

WATERTOWN, Mass. , May 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

– Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD ) at Angiogenesis, Exudation, and Degeneration 2022; Phase 2 clinical trial expected to initiate in Q3 2022 – – Phase 2 clinical trial

- Betta Pharmaceuticals to develop and commercialize EYP-1901 in China , Hong Kong , Macau and Taiwan ; EyePoint retains all global ophthalmic rights for EYP-1901 elsewhere - - Partnership strengthens 2020 license agreement between EyePoint and Betta affiliate, Equinox Sciences, for vorolanib in

WATERTOWN, Mass. , April 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live

WATERTOWN, Mass. , April 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker , Chief Executive

WATERTOWN, Mass. , April 18, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

WATERTOWN, Mass. , March 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted

New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savings WATERTOWN, Mass. , March 09, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to

WATERTOWN, Mass. , March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Isabelle

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022 , continuing positive safety and efficacy profile seen at six-month readout                –  Phase 2 trials for EYP-1901 in wet AMD and NPDR are

WATERTOWN, Mass. , March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker , Chief Executive

WATERTOWN, Mass. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live

- Continued positive efficacy and durability with stable visual acuity (VA) and optical coherence tomography (OCT) through eight-month follow-up - 41% of eyes remained rescue free up to nine months after a single dose of EYP-1901 - Positive safety data continued with no dose limiting toxicities, no

– Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting – – Phase 2 study for EYP-1901 in wet AMD expected to initiate in Q3

WATERTOWN, Mass. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Michael C.

ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU® and absorb the majority of EyePoint’s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all markets WATERTOWN, Mass.

WATERTOWN, Mass. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the closing of the previously

WATERTOWN, Mass. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the pricing of an underwritten

WATERTOWN, Mass. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has commenced an